PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2129011
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2129011
Plasmid DNA Manufacturing Market size was valued at US$ 2,478.52 Million in 2025, expanding at a CAGR of 17.98% from 2026 to 2033.
Plasmid DNA Manufacturing means the production of plasmids, which are DNA molecules in the form of circles of double-stranded DNA, by means of controlled biological and purification processes. Plasmid DNA is mostly produced for gene therapy, DNA vaccination, cell and gene therapy, recombinant proteins, and another research. The process of plasmid DNA manufacturing includes plasmid design and cloning, transformation of bacteria such as Escherichia coli and fermentation to increase the number of plasmids, harvesting, cell lysis, DNA purification, and testing and quality control. However, for clinical and commercial application, the process of manufacturing is carried out under GMP conditions to ensure compliance with the needed quality of the produced plasmid DNA.
Plasmid DNA Manufacturing Market- Market Dynamics
Growing gene and cell therapy pipeline drives market growth
The rapid expansion of gene and cell therapy pipelines is a major driver for the plasmid DNA manufacturing market. Plasmid DNA is an essential component in the manufacturing process of several viral vectors, including AAV and lentiviral vectors and is also used directly in some gene therapies. By the end of 2024, the gene-therapy pipeline contained approximately 1,424 preclinical candidates, 341 Phase I candidates, 306 Phase II candidates, and 35 Phase III candidates, suggesting there is a large pool of programs that will be entering clinical and commercial manufacturing, according to the Cogentia. As these therapies progress through the clinical phases, developers require increasing quantities of high-quality and GMP-grade plasmid DNA.
Leading pipeline programs in 2025 will be important drivers for the plasmid DNA manufacturing market. Vertex Pharmaceuticals's CASGEVY (exagamglogene autotemcel) is a major gene-editing therapy, while Sarepta Therapeutics's ELEVIDYS (delandistrogene moxeparvovec) represents a commercial AAV-based therapy; both are included in the FDA's list of approved cellular and gene therapy products. As such therapies continue to progress, there will be downstream requirements for plasmid DNA for use in the manufacturing process of viral vectors.
The Global Plasmid DNA Manufacturing Market is segmented on the basis of grade, development phase, application, disease, and Region.
The market is divided into three categories based on development phase: Pre-Clinical Therapeutics, Marketed Therapeutics and Clinical Therapeutics. The Clinical Therapeutics sector is expected to observe significant revenue growth in the Plasmid DNA Manufacturing market. The strong revenue outlook of the segment is primarily attributed to the rising number of therapeutic candidates entering pre-clinical development and subsequently progressing towards phase I-III clinical trials. Clinical grade plasmids, which are used in the manufacturing process of gene therapies, are increasingly in demand in connection with the production of viral vectors, gene-editing, or as a direct therapeutic moiety. The greater need for plasmid DNA of higher quality and compliance (GMP) is also linked to the greater need for consistent and large-scale production of plasmids for use in later-stage clinical trials.
The market is divided into four categories based on disease: Genetic Disorder, Cancer, Infectious Disease and Others. The Cancer segment would witness the highest revenue growth. The significant revenue growth is driven by the rising adoption of plasmid DNA in cancer gene treatments, cell therapies, viral-vector production and DNA-based cancer vaccinations. Plasmid DNA is a key starting material for the production of viral vectors and for the genetic modification of cells utilized in modern oncology therapies. The demand for high-purity and GMP-grade plasmid DNA is being driven by the growth of gene and cell therapy pipelines in the cancer area by pharmaceutical and biotechnology companies, especially as candidates move from pre-clinical research to clinical and commercial manufacture. This demand is also being fueled by rising use of tailored and targeted cancer medicines.
Plasmid DNA Manufacturing Market- Geographical Insights
North America dominates the market. One of the major growth drivers is the high and increasing cancer burden and growing interest in gene treatments, cell therapies, cancer vaccines and other novel biotherapeutics that use plasmid DNA as a critical input in their production process. In 2025, the National Cancer Institute estimates there will be 2,041,910 new cancer cases and 618,120 cancer deaths in the United States. Meanwhile, Canadian Cancer Statistics predicts that there will be 254,800 new cancer cases and 87,400 cancer deaths in Canada in 2025. This huge cancer burden is making pharmaceutical and biotech companies to ramp up their oncology focused gene and cell therapy pipeline which in turn is driving the requirement for high purity and GMP-grade plasmid DNA for manufacturing viral vectors and genetic engineering.
US Plasmid DNA Manufacturing Market- Country Insights
The US holds a majority of market share. One of the major drivers for this growth is the huge investment made by the leading pharmaceutical and biotech companies in development and manufacturing of gene and cell therapy which is leading to an increasing demand for high-quality plasmid DNA as a critical component in the production of viral vectors and genetic engineering. For instance, Novartis announced in April 2025 that it would invest $23 billion over five years in its U.S. manufacturing and research and development footprint including expanding capabilities supporting advanced therapies. Its U.S. network already includes a gene-therapy manufacturing facility in Durham, North Carolina.
Plasmid DNA manufacturing market is moderately consolidated with several key players and highly competitive, with competition focused on GMP manufacturing capacity, scale, quality of products, regulatory know-how, turn around time and end-to-end services. Key players include Charles River Laboratories, Danaher (Aldevron), Lonza, Thermo Fisher Scientific, GenScript ProBio, VGXI, Catalent, AGC Biologics, WuXi AppTec, Eurogentec, Kaneka, VectorBuilder.
In August 2026, 4basebio PLC, a specialist in enzymatically-produced, cell-free DNA for new genetic medicines, and Genezen, a best-in-class viral vector contract development and manufacturing organization (CDMO), announced an expanded, non-exclusive collaboration providing drug developers access to 4basebio's Research Use Only, High-Quality, and GMP-grade hpDNA(R) development and clinical programs. Through the collaboration, Genezen will offer access to 4basebio's synthetic DNA developed specifically for viral vector applications, creating a more streamlined path for cell and gene therapy developers to advance programs toward the clinic.
In January 2026, Bionova Scientific LLC, an Asahi Kasei company and a bespoke CDMO, has announced a strategic manufacturing alliance with Syenex, a genetic medicines platform company. The collaboration is focused on expanding global access to plasmid DNA used in next-generation gene delivery for advanced cell and gene therapies. Under the agreement, Bionova Scientific will serve as the preferred manufacturing partner for Syenex's delivery platforms. The partnership builds on Bionova's plasmid DNA manufacturing capabilities, which support lentiviral vector production and DNA templates for mRNA manufacturing. The companies said the alliance addresses ongoing challenges in pricing, quality, and supply-chain reliability of plasmid DNA.